Grip Molecular Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Series A
  • (Upcoming)

  • Latest Deal Amount
  • $15M

  • Investors
  • 7

Grip Molecular General Information

Description

Developer of a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-based diagnostic platform designed to provide molecular-level accuracy in infectious disease testing at the point of care or point of need. The company offers proprietary gene-editing chemistry integrated into a lateral flow format, enabling healthcare providers and decentralized testing environments to obtain laboratory-grade sensitivity and specificity in a simple, low-cost format.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1000 Westgate Drive
  • Suite 122
  • Saint Paul, MN 55114
  • United States
+1 (201)
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1000 Westgate Drive
  • Suite 122
  • Saint Paul, MN 55114
  • United States
+1 (201)

Grip Molecular Timeline

20232024202520262027
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Grip Molecular Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Later Stage VC (Series A) 01-Jan-2027 $15M Upcoming Pre-Clinical Trials
13. Later Stage VC 29-Oct-2026 Completed Pre-Clinical Trials
12. Seed Round 20-Feb-2026 Completed Pre-Clinical Trials
11. Grant 07-Mar-2023 Completed Product In Beta Test
10. Grant 28-Oct-2022 Completed Product In Beta Test
9. Grant 26-Oct-2022 Completed Product In Beta Test
8. Seed Round 11-Dec-2020 Completed Product In Beta Test
7. Accelerator/Incubator Completed Product In Beta Test
6. Accelerator/Incubator 29-Sep-2020 $50K $50K Completed Product In Beta Test
5. Grant 24-Aug-2020 $27K Completed Product In Beta Test
To view Grip Molecular’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Grip Molecular Patents

Grip Molecular Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026169752-A1 Crispr cascade methods for detecting target nucleic acids and kits and devices for practicing the same Pending 07-Feb-2025
WO-2026151762-A1 Methods and kits for detecting target nucleic acids using crispr associated proteases Pending 09-Jan-2025
US-11666907-B2 Methods, devices, and systems for detecting analytes Active 29-Sep-2017
US-12208390-B2 Methods, devices, and systems for detecting analytes Active 29-Sep-2017
US-20190262827-A1 Methods, devices, and systems for detecting analytes Active 29-Sep-2017 C12Q1/6825
To view Grip Molecular’s complete patent history, request access »

Grip Molecular Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Grip Molecular Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
gBETA Accelerator/Incubator Minority
EvoNexus Accelerator/Incubator Minority
Minnesota Department of Employment and Economic Development Government
University of Minnesota Office for Technology Commercialization University
University of Minnesota University
You’re viewing 5 of 7 investors. Get the full list »

Grip Molecular FAQs

  • When was Grip Molecular founded?

    Grip Molecular was founded in 2019.

  • Where is Grip Molecular headquartered?

    Grip Molecular is headquartered in Saint Paul, MN.

  • What is the size of Grip Molecular?

    Grip Molecular has 7 total employees.

  • What industry is Grip Molecular in?

    Grip Molecular’s primary industry is Diagnostic Equipment.

  • Is Grip Molecular a private or public company?

    Grip Molecular is a Private company.

  • What is Grip Molecular’s current revenue?

    The current revenue for Grip Molecular is .

  • How much funding has Grip Molecular raised over time?

    Grip Molecular has raised $15.4M.

  • Who are Grip Molecular’s investors?

    gBETA, EvoNexus, Minnesota Department of Employment and Economic Development, University of Minnesota Office for Technology Commercialization, and University of Minnesota are 5 of 7 investors who have invested in Grip Molecular.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process